This is an old revision of this page, as edited by Rod57(talk | contribs) at 14:45, 30 November 2016(→top: move 1 sentence up 2 lines). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:45, 30 November 2016 by Rod57(talk | contribs)(→top: move 1 sentence up 2 lines)
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]: 35 )